Space-grown glioblastoma organoids could help advance brain cancer treatments

by International Space Station U.S. National Laboratory

edited by Andrew Zinin

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process
Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

The GIST Add to Preferred Sources

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and is one of the most aggressive and deadly forms of cancer. It is difficult for surgeons to fully remove GBM because it often has microscopic "tentacles" that extend from the tumor into healthy brain tissue. GBM is also hard to treat because it creates an immunosuppressive microenvironment that helps the cancer evade immune attack and resist therapy.

To improve treatments, scientists must better understand the mechanisms involved in this complex disease, but accurately modeling GBM in the laboratory remains a challenge. Even sophisticated models called organoids, designed to mimic the structure and biology of human tumors, fail to fully reproduce key features of advanced GBM. When culturing cells on Earth, gravity causes them to settle, creating conditions that can interfere with the formation of complex 3D structures. That is why a team of researchers at the University of Notre Dame, led by Meenal Datta, took their research to space.

Leveraging the International Space Station (ISS) National Laboratory, the team grew three-dimensional organoids from GBM cells and innate immune cells that more closely replicate the structure and behavior of GBM tumors than organoids grown on Earth. In microgravity, cells can assemble into 3D structures with less interference from sedimentation, allowing researchers to better recreate the tumor architecture and cellular interactions seen in human disease. The results, recently published in PNAS, suggest that space-grown organoids could provide more realistic GBM models for studying cancer progression and testing new therapeutics.

In the investigation, which launched in 2024 with support from ISS National Lab commercial service provider Space Tango, the Notre Dame team grew GBM-immune organoids in space for 40 days before returning them to Earth for analysis. The researchers found that in the space-grown organoids, genes related to inflammation, immune responses, tissue remodeling and blood vessel formation were more active, and the levels of proteins associated with more aggressive GBM biology were higher. Additionally, the space-grown organoids showed a more immunosuppressive tumor microenvironment, a hallmark of advanced GBM that helps tumors resist the body's immune defenses.

Datta said the study also produced the first comprehensive multiomics data set from space-grown organoids, providing insights into gene activity, protein expression and how cells interact and are organized within the tissue.

"By growing GBM organoids on the ISS, we demonstrated that microgravity fuels a model phenotype that recapitulates human tumors better and faster than we achieve on the ground. This work helps lay the foundation for a new era of orbital oncology that moves cancer research from bedside to orbit and back again," said Datta, the Jane Schoelch DeFlorio collegiate professor of aerospace and mechanical engineering at the University of Notre Dame.

To build on these results, Datta and her team have launched two additional ISS investigations using patient-derived GBM-immune organoids, with the most recent flying on the SpaceX CRS-35 mission for NASA. By providing models that more fully capture the complex architecture and biology of advanced tumors, space-grown organoids could help researchers better understand GBM progression and accelerate the development of new therapies for patients on Earth.

"Datta and her team at the Tumor Immune Microenvironment and Mechanics Laboratory brought their expertise in one of the most aggressive and incurable brain cancers to space, where they demonstrated microgravity's unique ability to improve organoid models that function as 'mini tumors.' By combining human-derived glioblastoma cells with immune cells in space, this work could prove to be a landmark study in the effort to better understand and treat GBM and other aggressive cancers," said ISS National Lab chief scientist Michael Roberts.

Publication details

Alice Burchett Darantiere et al., Multi-omics and spatial analysis of microgravity-grown glioblastoma organoids reveal superior modeling of advanced disease after long-term spaceflight, Proceedings of the National Academy of Sciences (2026). DOI: 10.1073/pnas.2616218123

Journal information: Proceedings of the National Academy of Sciences

Key medical concepts

Glioblastoma

Clinical categories

OncologyNeurology Provided by International Space Station U.S. National Laboratory Who's behind this story?

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Space-grown glioblastoma organoids could help advance brain cancer treatments (2026, October 30) retrieved 30 October 2026 from https://medicalxpress.com/news/2026-10-space-grown-glioblastoma-organoids-advance.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.